Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
143.02(c) 144.42(c) 146.1(c) 146.95(c) 153.39(c) Last
835 561 732 446 527 704 1 156 537 1 447 130 Volume
-1.77% +0.98% +1.16% +0.58% +4.38% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 506 M - -
Net income 2021 -419 M - -
Net cash position 2021 2 642 M - -
P/E ratio 2021 -66,5x
Yield 2021 -
Sales 2022 2 230 M - -
Net income 2022 0,25 M - -
Net cash position 2022 2 547 M - -
P/E ratio 2022 1 362x
Yield 2022 -
Capitalization 27 907 M 27 907 M -
EV / Sales 2021 16,8x
EV / Sales 2022 11,4x
Nbr of Employees 2 092
Free-Float 99,1%
More Financials
Company
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV... 
More about the company
Ratings of Seagen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about SEAGEN INC.
07/30SEAGEN : Oppenheimer Adjusts Seagen PT to $210 From $208 Following Strong Q2 Res..
MT
07/29SEAGEN : Q2 Loss Widens Amid Higher Revenue, Reaffirms Guidance -- Stock Up 2% A..
MT
07/29SEAGEN : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
07/29SEAGEN : Management's Discussion and Analysis of Financial Condition and Results..
AQ
07/29Seagen Inc. Reports Earnings Results for the Second Quarter Ended June 30, 20..
CI
07/29SEATTLE GENETICS : Q2 Earnings Snapshot
AQ
07/29SEAGEN INC. : Results of Operations and Financial Condition (form 8-K)
AQ
07/29SEAGEN : Earnings Flash (SGEN) SEAGEN Reports Q2 Revenue $388.5M, vs. Street Est..
MT
07/29SEAGEN : Reports Second Quarter 2021 Financial Results
BU
07/29Seagen Inc. Provides Earnings Guidance for 2021
CI
07/29EARNINGS REACTION HISTORY : Seagen Inc, 50.0% Follow-Through Indicator, 7.3% Sen..
MT
07/16SEAGEN : Morgan Stanley Adjusts Price Target on Seagen to $167 From $173, Mainta..
MT
07/15SEAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
07/15Seagen Inc. Enters into A Commercial Supply Agreement Hovione FarmaCiencia SA
CI
07/12ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
AQ
More news
News in other languages on SEAGEN INC.
2020US-Konzern Merck & Co übernimmt Krebsforscher Velosbio
202010 Biotechs qui font parler d'elles
2020Aktien New York Schluss: Übernahmen bescheren starken Wochenauftakt
2020Aktien New York: Übernahme-Welle sorgt für einen starken Wochenauftakt
2020DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 14.09.2020 - 15.15 Uhr
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 153,39 $
Average target price 185,17 $
Spread / Average Target 20,7%
EPS Revisions
Managers and Directors
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Marc E. Lippman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-12.42%27 907
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
CUREVAC N.V.-39.24%21 497